Mortality & inpatient hospitalizations amongst patients with cardiac light-chain amyloidosis: results from a US administrative claims database

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Observational analysis assessed mortality and hospitalization rates in cardiac light chain amyloidosis patients, highlighting unmet needs.

1-year mortality was 9.1% among patients with cardiac light chain amyloidosis, indicating significant health challenges.
Among the cardiac-only group, the 1-year mortality was lower at 7.6%, suggesting better outcomes compared to those with renal involvement.
Daratumumab was used in 69.7% of patients, showing a mortality rate of 7.2%, demonstrating its potential impact.
The findings highlight ongoing health concerns for cardiac amyloidosis patients, especially those with cardiac and renal involvement.

Catini et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

View Full Paper

Ask AI

Bookmark

Authors

Observational analysis assessed mortality and hospitalization rates in cardiac light chain amyloidosis patients, highlighting unmet needs.

1-year mortality was 9.1% among patients with cardiac light chain amyloidosis, indicating significant health challenges.
Among the cardiac-only group, the 1-year mortality was lower at 7.6%, suggesting better outcomes compared to those with renal involvement.
Daratumumab was used in 69.7% of patients, showing a mortality rate of 7.2%, demonstrating its potential impact.
The findings highlight ongoing health concerns for cardiac amyloidosis patients, especially those with cardiac and renal involvement.

Catini et al. (2025) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark